LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ --...
Hence then, the article about novel agent ianalumab added to standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia )
Also on site :
- EU open to reversing Brexit after Burnham speech – but at a price
- Six Flags Magic Mountain Permanently Closes World-Famous X2 Roller Coaster Following Mounting Safety Concerns
- Jimmy Fallon Just Dropped a Brutal Title for Karoline Leavitt’s Hypothetical Memoir, and the Internet Is Having a Field Day